Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|August 2, 2004
- Pharmaceutical Technology-08-02-2004
- Volume 28
- Issue 8
Increased Outsourcing Driving Investments in CRO Industry
Author(s)Jim Miller
The contract services industry is fertile ground for the investment banking community this summer.
Advertisement
Articles in this issue
about 22 years ago
Stable Isotopic Characterization of Analgesic Drugsabout 22 years ago
August 2004about 22 years ago
E-Health Information Campaign Shapes Pharmaceutical Regulationabout 22 years ago
In the Spotlight-August 2004about 22 years ago
Interphex Delivers Packaging Solutionsabout 22 years ago
Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolatesabout 22 years ago
Decoding the US PharmacopeiaAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement